Patient Asks About Chelation

by | May 1, 2010

A PATIENT ASKS ABOUT CHELATION THERAPY

By Terry Chappell, M.D.

It was first thing on a Wednesday morning. Iva Chestpin walked slowly into my office gripping her husband’s arm for support. She looked exhausted. Iva was a 52 y.o. patient of mine, who came in for her yearly checkups and not much else. She was 20 pounds overweight and had been on low dose thyroid for 3 years. No smoking. A social drinker. She was a teacher, which means she was under stress. She had a family history of strokes and heart disease. I entered the exam room and sat beside her.

Dr. Terry Chappell: I understand you have been unusually tired for the last week. Do you have any chest pain or shortness of breath?

Iva Chestpin: That’s hard to say. I feel a fullness in my chest. Maybe it’s a pain. My breathing is a little short. I’m just wiped out. My muscles ache all over.

TC: Have you had anything like this before? Have you seen any other physicians?

Advertisement

IC: A few weeks ago I had a similar spell, but it didn’t last as long. I was really tired and I had the same feeling in my chest. My arms and legs didn’t ache like they do now. My husband insisted that I go to the ER. They brought in a cardiologist. He ran an EKG and some blood tests and said that I was not having a heart attack at the moment, but he wanted to run more tests to be sure. I was scared. I had a cousin who passed away when they put dye in his veins.

TC: As you know, Iva, I am an integrative family physician, not a cardiologist. I am really concerned about your symptoms, but I have a different approach. It’s true, like the cardiologist implied, that women with heart attacks often do not have crushing chest pain like men do. Recent evidence shows that women also are less likely to benefit from bypass surgery. You were absolutely right to question one test leading to another. An EKG leads to an echocardiogram, then a stress test, a catherization, and finally angioplasty with stents, or bypass.

IC: That’s what happened to me! The cardiologist told me that I would very likely die on my way to the car if I left. I didn’t want to, but I finally consented. The stress test was inconclusive. The catherization was awful, but somehow, I lived through it. They found two blockages, one 99% and the other 70%. They said there was nothing they could do about the 99% blockage, but they did a balloon procedure and left a stent in the artery that goes around the heart. They said I still might need a bypass later.

TC: Did they say anything about the left main or the left anterior descending arteries?

IC: Yes, that sounds familiar. They said one was okay and the other was normal, only 30% blocked.

TC: Did they say if you had a heart attack?

IIC: No, they said they saved my life. The surgery was just in time.

TC: We’ll send for the records to get the details. Let me comment on what you have told me so far. First, you had to have developed side channels, or what we call collateral circulation, around the artery that was totally blocked, or you would probably be dead. Second, more than three quarters of heart attacks occur in arteries that are only 30-50% blocked, but they leak some fatty material from the plaque. The blood stream reacts to the leakage to form a clot that suddenly blocks the artery. This is called a “vulnerable plaque”, and it causes a part of the heart muscle to die. If it is not fatal, a scar is left in place that can cause the heart to beat less efficiently. An artery that is blocked 70-90% might not be as dangerous as a vulnerable plaque, because over time it has had a chance to develop collateral circulation to supply the tissues downstream.

No surgeon operates on arteries that are only 30% blocked. Often a plaque that size is read as “normal”, just like yours was. But it might make more sense to stabilize these lesser plaques than operate on the arteries with major blockages. The left main and the left anterior descending arteries are more dangerous than other arteries if significantly obstructed, but that wasn’t your situation.

IC: I thought I wasn’t getting the whole story. What should I have done?

TC: You didn’t do anything wrong, Iva. Doctors are in a position of power. They said you were going to die if you didn’t go under the knife. I don’t suppose they mentioned the OAT study. OAT stands for the Open Artery Theory. Researchers wanted to prove that if they opened arteries with surgery after a heart attack, fewer patients would die. Instead, the results shook the surgery world, at least for a short time. Patients treated only with medicines actually did somewhat better than those who had surgery. You would think the OAT study results would have eliminated most surgery after a heart attack, especially since many other studies have shown that patients do not live longer with surgery than with medical treatment. But nothing changed. Surgery is still considered first-line treatment for coronary artery disease.

IC: Next came the drugs. They gave me two blood pressure pills, aspirin, and two more drugs they are always talking about on TV. I think one was a statin. The other was Plavix. I almost got my heart attack when I got the bill. They assured me that side effects were rare, and insisted that I needed to take all the drugs religiously. Did that mean I was supposed to pray before I took them? I’m sorry. I know that’s an awful joke, but maybe it would have helped. Within 3 days, I was miserable. My muscles ached all over, and I could barely get out of bed. The cardiologist told me to keep taking the drugs. I don’t think he believed how horrible I felt.

The only one that understood was the nurse at the doctor’s office. She told me not to tell anyone what she said, but she suggested I come see you.

TC: I appreciate her advice, Iva. Unfortunately, most cardiologists minimize the side effects of statin drugs. They also tend to undervalue the role of lifestyle changes compared to drugs, and they are close-minded about chelation therapy and nutritional supplements. Various studies have calculated that 5-30% of improvements in vascular disease over the years is attributed to drug therapy, and 57-62% is due to the basic lifestyle changes like stopping smoking, a healthy diet, weight loss, exercise, and coping with stress. If we do nothing else, we have to put these factors on your side. Next we will get you a natural supplement to replace the drug that is making you feel miserable. We will examine and treat your cardiac risk factors. Then we’ll talk about chelation therapy and other integrative therapies that have worked very well for many patients in our practice.

IC: I know I can do a lot better, especially with my weight and exercise. Do I have to take all the drugs the doctors gave me.

TC: Well, Iva, each of the drugs prescribed have scientific evidence that they might reduce the chances of future heart attacks. We don’t want to ignore that evidence. But if the impact of the drugs is not very great, and it often isn’t, and we are doing a lot of other interventions, we can minimize the drugs. This is especially true if the drugs have significant side effects that interfere with your quality of life. If they are expensive and necessary, we can often prescribe a generic. You can see from Figure 1, my heart chart, there are many, many factors that we can examine and modify. We don’t test all of these factors for every patient, but the more of them we can put on your side, the better. With a comprehensive approach, usually including chelation, we can often do very well without a whole lot of medications.

You have been given two of the most common and expensive cardiac drugs, Crestor and Plavix. Our tests show similar benefits with red yeast, coenzymeQ10 and niacin to reduce inflammation, raise HDL, and lower LDL levels. We can use fish oils and nattokinase to cut down the risk of blood clots. Some of your fatigue and most of your aching muscles are probably due to Crestor. Plavix can certainly reduce the clotting tendency after stents, especially within the first 6-12 months, but it also increases the risk of brain hemorrhage.

IC: That sounds a lot better to me. I’m really interested in chelation therapy. I’ve heard it can clean the plaque out of my arteries, like a rotor-rooter.

TC: Unfortunately, that’s an exaggeration. Chelation therapy, as we give it, consists of a series of IV’s that pulls toxic metals such as lead from the tissues into the urine. Many studies have identified lead as a factor that leads to hypertension and vascular disease. In fact more than one article has shown that the amount of lead in your body is directly proportional to how high your blood pressure is. Mercury, arsenic, cadmium and aluminum have also been implicated. Toxic metals are some of the most common pollutants in the environment. They seep into the food supply. If there is a recent exposure, they can be detected in the blood. But soon after entering the body they are stored in the fat cells, bone, or brain. We find that the best way to detect them is to do a challenge test. We give you a chelating agent and measure the amount of metals that comes out into the urine. One of the primary actions of chelation therapy is to lower the burden of toxic metals.

Chelation has other effects too. By lowering the serum calcium temporarily, it can reduce the clotting tendency much more safely than Plavix. Some of our smaller studies indicate that a dip in the serum calcium triggers a biochemical cascade that reduces the plaque size to some degree. This process might also make a vulnerable plaque less likely to leak and cause a heart attack or stroke.

Chelation doesn’t completely eliminate the plaque. But it appears to make the plaque much less likely to cause heart attacks and strokes.

IC: Does oral chelation work the same way? I see it advertised all the time. I’d sure rather take some pills than get jabbed with a needle.

TC: Oral chelation and the IV push that some doctors give over a few minutes both contain calcium EDTA. All of the published studies on vascular disease have used disodium EDTA with magnesium. Both forms of EDTA remove metals, although technically only the calcium version is FDA-approved for this purpose. The concern about using calcium EDTA is that you do not get a lowering of the serum calcium, which is the mechanism that inhibits platelet aggregation and might stabilize the vulnerable plaque. Another problem with oral chelation is that only 5-10% is absorbed, unless an unpleasant-tasting lipid material is added to it. Thus oral chelation might protect you against excessive lead in your digestive tract after an exposure with contaminated food, but I do not believe it is adequate for removing metals that are already doing damage in the body.

It is really important that doctors and their nurses who give chelation therapy be very well-trained. If disodium EDTA were given rapidly as an IV injection instead of a slow drip, it would be dangerous. No properly trained team would make such a mistake. When given according to protocol, disodium EDTA with magnesium is much safer than most prescription drugs.

The biggest concern about chelation therapy is that we do not overload the kidneys by giving too high a dose too fast. We are very careful to avoid that problem by checking the urine and creatinine regularly. If there is any sign of kidney strain, we lower the dose. As long as we don’t overload the kidneys, the kidney function usually gets better with EDTA treatment rather than worse, which has been published in major medical journals. We presume that the reason kidney function improves is that we are improving circulation to the kidneys.

IC: Have there been studies on chelation therapy that prove it to be effective?

TC: There have been many studies, the vast majority of them showing benefit with chelation. A few of the studies by critics of the therapy showed that patients improved to some degree, but the conclusions were still negative. With help from some of my colleagues, I have published several studies. One small study showed that chelation reduced brachial artery stiffness, which corresponds to the vulnerable plaque. Another was a study of studies, called a meta-analysis. That one showed that patients treated with chelation had measurable improvements with non-invasive tests. Third, we compared vascular patients who had been treated with chelation with those treated with angioplasty, bypass, and/or medicines alone and found that the chelation group had a much lower incidence of heart attacks, subsequent surgery, and premature death.

None of the studies to date were large enough to have statistical significance, according to expert analysis. Thus, the National Institutes of Health funded a major study called the Trial to Assess Chelation Therapy (TACT). That study is still in progress. We will know the results in about 4 years. Over 30,000 treatments have been administered in the study. All we know so far is that there have been no safety concerns.

Iva’s husband: What if chelation doesn’t work for my wife?

TC: In my experience, the program we have been discussing is very helpful 85-90% of the time. Look again at the heart chart. Keep in mind, most of these therapies are in addition to the EDTA protocol. They are not part of TACT. With a comprehensive but also individualized approach, I fully expect to help you stabilize your disease and keep it under control for a long time. Since you have already had surgery, we need to keep your arteries from closing up again, which they tend to do. You must also realize, however, that no therapy succeeds 100% of the time. Rarely, additional surgery is still needed, despite our best efforts.

Our goal is to give you the best, the safest, the most cost-effective treatment that we can. We want to help you to feel better, live longer and avoid the serious side effects that can come from drugs and surgery. For thirty years, we have seen many, many patients get exactly these benefits with chelation therapy, lifestyle changes, and a thorough nutritional program.

IC: Thanks, Dr. Chappell. I can’t wait to get started.

References

1. Alfredsson J, Sederholm-Lawesson S, Stenestrand U, Swahn E. Although women are less likely to be admitted to coronary care units, they are treated equally to men and have better outcome. Acute Cardiac Care. 2009;3:173-80.

2. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355:2395-2407.

3. Malaty W. What does the evidence tell us about treating very-high-risk patients to an LDL <70 mg/dl? J of Family Practice. 2009;58:665-67.

4. Kaufmann JM. Misleading recent papers on statin drugs in peer-reviewed medical journals. J Am Physicians and Surgeons. 2007;12:7-9.

5. Chiuve SE, McCullough ML, Sacks FM, et al. Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications. Circulation. 2006;114:160-167.

6. Schiff GD, Galanter WL. Promoting more conservative prescribing. JAMA. 2009;301:865-67.

7. Menke A, Muntner P, Batuman V, et al. Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. Circulation. 2006;114:1388-94.

8. Nash D, Magder L, Lustberg M, et al. Blood lead, blood pressure and hypertension in perimenopausal and post menopausal women. JAMA. 2003;289:1523-32.

9. Navas-Acien A, Silbergeld EK, Pastor-Barriuso R, Guallar E. Arsenic exposure and prevalence of type 2 diabetes in US adults. JAMA. 2008;300:814-22.

10. Lin JL, Lin-Tan DT, Hsu KH, et al. Environmental lead exposure and progresssion of renal diseases in patients without diabetes. N Engl J Med. 2003;348:277-86.

11. Zucker MB, Grant RA. Nonreversible loss of platelet aggregability induced by calcium deprivation. Blood. 1978;52:505-13.

12. Chappell LT. Should EDTA chelation therapy be used instead of long-term clopidogrel plus aspirin to treat patients at risk from drug-eluting stents? Altern Med Rev. 2007;12:152-158.

13. Cranton EM, ed. A textbook on EDTA chelation therapy, second edition. Charlottesville, Va, Hampton Roads, 2001.

14. Chappell LT, Angus RC, Stahl JP, Evans RE. Brachial artery stiffness testing as an outcome measurement for EDTA treated patients with vascular disease. Clinical Prac Alt Med 2000;1:225-29.

15. Chappell LT, Stahl JP. The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis. J Adv Med 1993;6:139-63.

16. Chappell LT, Shukla R, Yang J, Blaha R, et al. Subsequent cardiac and stroke events in patients with known vascular disease treated with EDTA chelation therapy: a retrospective study. Evid Based Integrative Med 2005;2:27-35.

17. Clay B. Study of chelation therapy should not be abandoned. J Am Physicians and Surgeons 2009;14:51-57.

Author

  • After graduating from the University of Michigan medical school, Dr. Chappell became certified by the American Board of Family Medicine and later by the National Board of Physicians and Surgeons. He is the author of Questions from the Heart and has published many articles showing the effectiveness of chelation therapy for vascular disease in the Townsend Letter and in other journals. He has run a blog discussing medical news for 10 years.  He has served as President of the International College of Integrative Medicine and of the American College of Advancement in Medicine and has frequently lectured for both organizations. Dr. Chappell ran an Institutional Review Board for ICIM in the 1990s. He has provided testimony for six medical boards, one Congressional hearing, the Danish Supreme Court, and the Federal Trade Commission. Twice he served on NIH review committees and later as an investigator for the Trial to Assess Chelation Therapy.

    View all posts

Already Subscribed?

Search

Formatting updates are ongoing for older articles.

Author

Featured Articles

Where are your Clinical Trials?

It has proven to be difficult, if not impossible, to proceed to full-scale randomized controlled trials (RCTs) for most of the natural methods that cannot be patented or otherwise monopolized. 

A Renewed Focus on Self-Help for Healing

As the producer of The Moss Report, the year leading up to the Covid-19 pandemic was filled with anticipation and excitement. We had invested years of hard work and significant resources into two major projects: our feature film, Immunotherapy: The Battle Within, and...

Issue Archives

Event Calendar

  • Integrative Cancer Symposium 2026 – Believe BIG

    Sheraton, Towson MD Towson, MD, United States

    Optimize Your Health. Transform Your Future. Join us for this dynamic one-day experience designed for anyone seeking to take a proactive, whole-body approach to health. Integrative oncology is a dynamic and rapidly evolving field, unveiling groundbreaking discoveries and new possibilities every day. This year’s one-day conference will take place at the Sheraton in Towson, Maryland from 9am – 5pm and offers both in-person and virtual attendance options. This event brings together leading experts in integrative oncology, functional medicine, and wellness. Discover cutting-edge approaches to prevention, treatment, recovery, and whole-person wellness at the Integrative Cancer Symposium Believe Big 2026. Learn from leading clinicians, researchers, and innovators in integrative oncology as they explore emerging therapies, metabolic and lifestyle approaches, mistletoe therapy, nutrition, environmental health, mindset, and more. Whether you are navigating cancer personally, supporting a loved one, or simply looking to optimize your health and reduce future risk, this powerful one-day experience offers practical tools, fresh insights, and meaningful connection.

  • PLMI 14th Annual Thought Leaders Consortium

    Loews Coronado Bay Resort 4000 Coronado Bay Rd, Coronado, CA, United States

    The 14th Annual Thought Leaders Consortium marks the culminating chapter of PLMI’s three-year exploration into the biology of immuno-metabolism, epigenetic regulation, and human longevity. Building on the 2024 and 2025 Consortia—which reframed chronic disease through immune-metabolic dysfunction and diet- and environment-driven epigenetic remodeling—this year’s gathering places mitochondria at the center of health, disease, and aging. Once viewed simply as the cell’s energy producers, mitochondria are now recognized as dynamic, epigenetically responsive organelles that integrate nutrition, environmental exposures, immune activation, stress signaling, physical activity, and circadian inputs into a unified metabolic-immune system. Disruption of mitochondrial function is increasingly implicated in fatigue syndromes, chronic pain, immune dysregulation, neurodegeneration, infertility, metabolic disease, accelerated aging, and diminished stress resilience. This advanced, science-driven Consortium convenes world-leading experts to explore mitochondrial biology as the cornerstone of immuno-metabolic resilience. Attendees will gain cutting-edge insights into mitochondrial signaling, mito-nuclear communication, and metabolic flexibility—alongside clinically actionable frameworks for restoring cellular vitality, reversing biological aging trajectories, and extending healthspan. Through deep scientific exploration and translational clinical strategy, the 2026 Thought Leaders Consortium will equip practitioners and researchers with the knowledge needed to redefine assessment, intervention, and long-term outcomes in personalized and lifestyle medicine.

    $650
  • Practical Clinical Skills in Neurotransmitter Optimization: Clinical Herbalism for Mood, Cognition & Aging

    Virtual Event

    Join us for the second part of this two-part virtual symposium! Mental health and neurocognitive disorders remain among the most prevalent and inadequately addressed challenges in modern clinical practice.  This intensive, expert-led symposium provides a comprehensive, clinically grounded framework for integrating herbal and nutraceutical strategies into mental health care. Attendees gain a working understanding of how targeted herbal interventions modulate key neurotransmitter systems, including serotonin, dopamine, GABA, and cortisol, and how to apply these therapies strategically, whether as adjuncts to pharmaceuticals or as standalone options. Clinical applications span a wide spectrum, from anxiety and depression to Parkinson’s-related motor symptoms and age-associated cognitive decline, with a strong emphasis on practical implementation and patient-specific protocol design.

Related Posts

When Screens Replace Connection: Impact on Children’s Brains

By Erik Peper, PhD, BCB, Stoyan Vezenkov, PhD, Violeta Manolovab, Lauren Mason, PhD and Richard Harvey, PhD – The empirical record on educational technology in early and primary education has not delivered on its promises—math and reading scores have declined while screen use in classrooms has risen, as the US NAEP data and Sweden’s recent reversal of its “digital-first” education policy make plain.

Read More

The Pharmacy of the Sacred Forest: Medicinal Plants and Ancestral Wisdom of the Jola Healers (Gambia)

By Dr. Josep Lluís Berdonces – “Out of sight, out of mind,” goes a traditional proverb that Malang often repeats. The destruction of sacred forests, the loss of local languages, the disappearance of wise elders without passing on their knowledge: all of this represents a cultural and therapeutic catastrophe of incalculable dimensions.

Read More

0 Comments

Submit a Comment

Pin It on Pinterest

Share This